Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Shares Climb 6.25 Percent on Strong Q2 Revenue Growth

NEW YORK, Aug. 5 (GenomeWeb News) - Shares in Accelrys were up 6.25 percent, or $.33, at $5.61 in mid-afternoon trading after the company reported a 31-percent increase in second-quarter revenue and a narrowed net loss.

 

As  GenomeWeb News reported, total revenues for the period ended June 30 increased to $18.6 million from $14.2 million during the same period last year. This quarter's revenues included deferred revenue from the company's switch to subscription accounting.

 

Product development costs increased to $4.9 million, up from $4.1 million during the year-ago quarter.

 

Accelrys' net loss fell 40 percent to $3.7 million, or $.14 per share, from $6.2 million, or $.25 per share, for the second quarter of last year. Last year's loss included $1.1 million from discontinued operations.

 

As of June 30, Acclerys had $56.3 million in cash, restricted cash, cash equivalents, and marketable securities.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.